Axitinib (AG 013736)

Name: Axitinib (AG 013736)
Brand: Selleck Chemicals
SKU: S1005
Rating: 5 (115 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1005

115 publications

CAS No. 319460-85-0

Axitinib (AG 013736) is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Selleck's Axitinib (AG 013736) has been cited by 115 publications

Cell, 2018, 173(1):74-89

PubMed: 29570999 ( click the link to review the publication )

Cell, 2018, 173(1):117-129

PubMed: 29570992 ( click the link to review the publication )

Cancer Discov, 2012, 2(4):344-55

PubMed: 22576211 ( click the link to review the publication )

J Clin Invest, 2021, 131(8)139434

PubMed: 33855973 ( click the link to review the publication )

Theranostics, 2021, 11(10):4975-4991

PubMed: 33754039 ( click the link to review the publication )

Mol Syst Biol, 2021, 17(9):e10426

PubMed: 34486798 ( click the link to review the publication )

Elife, 2021, 10e67315

PubMed: 34085926 ( click the link to review the publication )

Cancers (Basel), 2021, 13(9)2009

PubMed: 33921957 ( click the link to review the publication )

J Clin Endocrinol Metab, 2021, dgab020

PubMed: 33524147 ( click the link to review the publication )

Hum Mol Genet, 2021, ddab011

PubMed: 33438013 ( click the link to review the publication )

Front Oncol, 2021, 11:650052

PubMed: 34094940 ( click the link to review the publication )

Cancer Immunol Immunother, 2021, 10.1007/s00262-021-02992-7

PubMed: 34160685 ( click the link to review the publication )

Cancer Gene Ther, 2021, 10.1038/s41417-021-00345-1

PubMed: 34088993 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Biomedicines, 2021, 9(8)949

PubMed: 34440153 ( click the link to review the publication )

Biomedicines, 2021, 9(6)627

PubMed: 34072926 ( click the link to review the publication )

Oncotarget, 2021, 12(7):674-685

PubMed: 33868588 ( click the link to review the publication )

Nat Commun, 2021, 12(1):808

PubMed: 33547292 ( click the link to review the publication )

Dev Biol, 2021, 473:80-89

PubMed: 33577829 ( click the link to review the publication )

Mol Cell, 2020, 80(6):1104-1122.e9

PubMed: 33259812 ( click the link to review the publication )

Clin Cancer Res, 2020, 20 pii: clincanres

PubMed: 32312893 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Biomaterials, 2020, 237:119793

PubMed: 32044521 ( click the link to review the publication )
Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:578

PubMed: 32733887 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Aging (Albany NY), 2020, 13(1):1096-1119

PubMed: 33291075 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Toxicol In Vitro, 2020, 71:105063

PubMed: 33271325 ( click the link to review the publication )

Molecules, 2020, 26(1)E35

PubMed: 33374788 ( click the link to review the publication )

Burns Trauma, 2020, 8:tkaa025

PubMed: 33150188 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Cell Rep, 2020, 32(2):107906

PubMed: 32668247 ( click the link to review the publication )

Exp Ther Med, 2020, 19(2):1336-1342

PubMed: 32010307 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(4):2402-2415

PubMed: 31957261 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

Dev Cell, 2019, 48(2):151-166.e7

PubMed: 30639056 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(25):12353-12362

PubMed: 31152134 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2019, 101021/acsami9b20178

PubMed: 31816241 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Int J Cancer, 2019, 145(7):1991-2001

PubMed: 30848481 ( click the link to review the publication )

Lab Chip, 2019, 19(12):2071-2080

PubMed: 31049508 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):322

PubMed: 31331377 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-18-1319

PubMed: 31594826 ( click the link to review the publication )

Hum Mol Genet, 2019, 10.1093/hmg/ddz152

PubMed: 31518391 ( click the link to review the publication )
Pharmacol Res, 2019, 144:292-305

PubMed: 31048033 ( click the link to review the publication )

J Immunol, 2019, 203(10):2630-2643

PubMed: 31586036 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28810

PubMed: 31093976 ( click the link to review the publication )

Int J Nanomedicine, 2019, 14:441-455

PubMed: 30666106 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

Plast Reconstr Surg, 2019, 143(1):126-135

PubMed: 30303928 ( click the link to review the publication )

Naunyn Schmiedebergs Arch Pharmacol, 2019, 10.1007/s00210-019-01746-8

PubMed: 31655854 ( click the link to review the publication )

Commun Biol, 2019, 2:170

PubMed: 31098403 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(9):1523-1534

PubMed: 31266784 ( click the link to review the publication )

Assay Drug Dev Technol, 2019, 17(4):167-177

PubMed: 31184962 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5009

PubMed: 30479336 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):974

PubMed: 30250188 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1405-1415

PubMed: 29695637 ( click the link to review the publication )

J Cell Physiol, 2018, 233(3):2067-2074

PubMed: 28294324 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2018, 314(5):C589-C602

PubMed: 29351406 ( click the link to review the publication )

Cell Biol Int, 2018, 42(11):1511-1522

PubMed: 30080297 ( click the link to review the publication )

Biomed Chromatogr, 2018, 32(6):e4184

PubMed: 29283445 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Oncotarget, 2018, 9(89):35962-35973

PubMed: 30542510 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(11):2934-2939

PubMed: 28246332 ( click the link to review the publication )

Cancer Res, 2017, 77(5):1212-1226

PubMed: 28087600 ( click the link to review the publication )

Theranostics, 2017, 7(16):3972-3988

PubMed: 29109792 ( click the link to review the publication )

Oncogene, 2017, 10.1038/onc.2017.132

PubMed: 28481872 ( click the link to review the publication )

Br J Cancer, 2017, 117(5):e3

PubMed: 28704838 ( click the link to review the publication )
Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(7):858-869

PubMed: 28669525 ( click the link to review the publication )

Hum Mol Genet, 2017, 26(22):4375-4387

PubMed: 28973155 ( click the link to review the publication )

Front Oncol, 2017, 7:182

PubMed: 28879167 ( click the link to review the publication )

Cell Biosci, 2017, 7:43

PubMed: 28852468 ( click the link to review the publication )

Eur Radiol, 2017, 27(3):918-926

PubMed: 27287476 ( click the link to review the publication )

Chem Biodivers, 2017, 14(3)

PubMed: 27936296 ( click the link to review the publication )

Oncotarget, 2017, 9(5):5529-5544

PubMed: 29464016 ( click the link to review the publication )

Neural Regen Res, 2017, 12(11):1816-1822

PubMed: 29239327 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(8):1940-50

PubMed: 26578684 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(33):9339-44

PubMed: 27482107 ( click the link to review the publication )

Cancer Res, 2016, 76(11):3200-10

PubMed: 27197162 ( click the link to review the publication )

Cancer Res, 2016, 76(1):117-26

PubMed: 26677977 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

J Immunol, 2016, 197(2):504-16

PubMed: 27279371 ( click the link to review the publication )

Sci Rep, 2016, 6:24453

PubMed: 27076230 ( click the link to review the publication )

CNS Neurosci Ther, 2016, 22(6):440-50

PubMed: 26861512 ( click the link to review the publication )

Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Mol Nutr Food Res, 2015, 59(11):2255-66

PubMed: 26255647 ( click the link to review the publication )

Sci Rep, 2015, 5:16622

PubMed: 26564777 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2015, 56(5):3140-8

PubMed: 26024097 ( click the link to review the publication )

PLoS One, 2015, 10(10):e0140310

PubMed: 26461489 ( click the link to review the publication )
PLoS One, 2015, 10(6):e0128897

PubMed: 26042424 ( click the link to review the publication )

Anal Chem, 2014, 86(17):8842-9

PubMed: 25118958 ( click the link to review the publication )

J Cell Biochem, 2014, 10.1002/jcb.25066

PubMed: 25536282 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:1107-23

PubMed: 25170251 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85759

PubMed: 24454929 ( click the link to review the publication )

Gene Expression Patterns , 2014, 16(2):93-103

PubMed: 25460514 ( click the link to review the publication )

Oncotarget, 2014, 5(16):6801-15

PubMed: 25149535 ( click the link to review the publication )

J Nucl Med, 2013, 54(9):1630-6

PubMed: 23907757 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Br J Cancer, 2013, 110(4):894-8

PubMed: 24398510 ( click the link to review the publication )

Development, 2013, 140(20):4214-25

PubMed: 24026121 ( click the link to review the publication )

Acta Oncol, 2013, 53(5):637-45

PubMed: 24041258 ( click the link to review the publication )

Histochem Cell Biol, 2013, 139(3):431-45

PubMed: 23052841 ( click the link to review the publication )

J Labelled Comp Radiopharm, 2013, 56(2):42-9

PubMed: 24285281 ( click the link to review the publication )

Glia, 2012, 60(6):936-47

PubMed: 22431192 ( click the link to review the publication )

Cancer Sci, 2012, 103(3):433-8

PubMed: 22098620 ( click the link to review the publication )

Mol Med, 2012, 18:887-98

PubMed: 22549112 ( click the link to review the publication )

Cells Tissues Organs, 2012, 196(3):195-205

PubMed: 22433970 ( click the link to review the publication )

J Biomol Screen, 2011, 16(2):141-54

PubMed: 21297102 ( click the link to review the publication )

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description

Features

Superior as second-line therapy relative to sorafenib (current standard-of-care).

Targets

VEGFR1/FLT1 ^[1] (Porcine aorta endothelial cells)	VEGFR2/Flk1 ^[1] (Porcine aorta endothelial cells)	VEGFR2/KDR ^[1] (Porcine aorta endothelial cells)	VEGFR3 ^[1] (Porcine aorta endothelial cells)	PDGFRβ ^[1] (Porcine aorta endothelial cells)	View More
0.1 nM	0.18 nM	0.2 nM	0.1 nM-0.3 nM	1.6 nM	View More

In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). ^[2]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
EoL-1-cell	Ml;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH70[\|JKSzVyPUCuNFAxODVzMzFOwG0>	M3vIe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
NCI-H1703	M4\u[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mn;2TWM2OD1yLkCwNFkxOiEQvF2=	NED0fVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
KASUMI-1	NFPvPVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoOyTWM2OD1yLkCwOlgzKM7:TR?=	NXvpXmhGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
CGTH-W-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUHJR\|UxRTBwMEC3NlIh\|ryP	NWHQW2FERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
A204	MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXfWXXJxUUN3ME2wMlAxQTl{IN88US=>	MnfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
HOP-62	NF;LR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlLMTWM2OD1yLkGwPFM3KM7:TR?=	MoPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
H-EMC-SS	M4\DUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXrRS5Q6UUN3ME2wMlEyODB3IN88US=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
KU812	NIjYZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlzzTWM2OD1yLkG2OVc4KM7:TR?=	NWPVfnNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
EM-2	NGPl[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mlq3TWM2OD1yLkG2PFE3KM7:TR?=	M4TzTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
LAMA-84	M3TEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NI\Vb4dKSzVyPUCuNVc3PjVizszN	MoXUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
JAR	Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVTpO4lsUUN3ME2wMlI{QTh7IN88US=>	NH;OR4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
G-361	NH\5eoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVvPblZmUUN3ME2wMlMzOzJ3IN88US=>	M13oPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
KG-1	M3HqW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV\JR\|UxRTBwM{e2OFIh\|ryP	MkjiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
BV-173	M3q0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkLqTWM2OD1yLkO5N\|Ih\|ryP	NV;lNGQ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
K5	NEDXSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVq3SlhQUUN3ME2wMlQzOTJ5IN88US=>	MmDTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
MEG-01	NET6[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYXJR\|UxRTBwNEKzOlEh\|ryP	NW\YWnZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
MFM-223	M4roVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFe4Wm9KSzVyPUCuOFQ4PzZizszN	NID5PFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
BE-13	NVzKV5ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFSzNYxKSzVyPUCuOVExODhizszN	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NEC8	NV3tN2hKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2rnSmlEPTB;MD63NlEyOyEQvF2=	MknKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
SW756	NFe3emFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mnu3TWM2OD1yLkm5PFQ3KM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
A2780	M2\MUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmPhTWM2OD1zLkCxNVQ3KM7:TR?=	Ml3MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
NB14	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmTOTWM2OD1zLkCxPFAyKM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
H4	NYLxTHVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXO0[W1vUUN3ME2xMlA3PDJ{IN88US=>	MkjMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
SK-OV-3	NW\6fJk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NETxT3hKSzVyPUGuNFY3OzNizszN	NWXZeVl4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
AN3-CA	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MknETWM2OD1zLkC4N\|g6KM7:TR?=	NHT2bWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
A427	M2PZSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUW5NZMxUUN3ME2xMlExOzhzIN88US=>	NV7yeYJuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
ES7	NIrCe3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3zUWmlEPTB;MT6xNVM{PCEQvF2=	MlTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
AGS	M4mwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXn3S3pDUUN3ME2xMlEyOzl3IN88US=>	M2PXUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
G-402	NITTemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWHJR\|UxRTFwMUS2PVQh\|ryP	NVXLZ2NMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
ES5	M3nLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NULkO5YzUUN3ME2xMlE4OjR6IN88US=>	NVfZ[XprRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
DEL	NHTTdGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXrJR\|UxRTFwMkW0OVch\|ryP	NEOybnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
NB10	NX75eVBzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2L3O2lEPTB;MT6zNlU2PyEQvF2=	M13mXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
NCI-H1581	NIf0ZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYXJR\|UxRTFwM{mwOFIh\|ryP	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
D-566MG	MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1LYZ2lEPTB;MT60NFY5OyEQvF2=	NHT6V5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
LXF-289	NX\semVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{PxVmlEPTB;MT60N\|k6PiEQvF2=	M2XBZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
BT-549	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGD6VW5KSzVyPUGuOVY6ODlizszN	M4rIWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
NKM-1	M3vyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MojVTWM2OD1zLk[wOVU3KM7:TR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
SW780	M2n6NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1v3XmlEPTB;MT62OVE2QCEQvF2=	NFf3T5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
NCI-H292	M1TIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUHJR\|UxRTFwNk[zPFMh\|ryP	M1zQOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
HMV-II	NVjVS4RnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYLXZ2JxUUN3ME2xMlcxPDh6IN88US=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
ALL-PO	Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV\W[WEyUUN3ME2xMlgxODF3IN88US=>	NGD2T5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
UACC-257	M4rXO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWjJR\|UxRTFwOEKxOlMh\|ryP	Mn;LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
PA-1	MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mom2TWM2OD1zLkiyO\|I2KM7:TR?=	M{[3flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
HD-MY-Z	NYC4WJJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYnJR\|UxRTFwOE[yPFEh\|ryP	MoPsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
HSC-4	NIXNcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUe3WWdNUUN3ME2xMlk{QDN7IN88US=>	NGjzW5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
GCT	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF[0N\|dKSzVyPUKuNFA6OTZizszN	MoPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
RT-112	NXW3T2VOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUPTO3hEUUN3ME2yMlE{PDJ2IN88US=>	MnSxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
A172	MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWT5eWQ1UUN3ME2yMlE{PjB4IN88US=>	M13wNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
HCE-T	NGOwc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mo\YTWM2OD1{LkKwOVk5KM7:TR?=	Mn;kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
YH-13	M37MTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX2wPIJPUUN3ME2yMlIyPjdzIN88US=>	NWjxS3ExRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
DK-MG	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3rrTGlEPTB;Mj6yN\|g{PCEQvF2=	NFryeIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
ACN	M4W0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX\JR\|UxRTJwMkO4O\|Uh\|ryP	M2Dl[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
VA-ES-BJ	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF\IOGpKSzVyPUKuNlQ6PTdizszN	NGnGOpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
L-363	M3exO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUDQeYNxUUN3ME2yMlI5ODZzIN88US=>	NYDoUWVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
HuH-7	MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXXJR\|UxRTJwNEKxOlUh\|ryP	NVm4SVVSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
A4-Fuk	M2KxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkTlTWM2OD1{LkS3NVY5KM7:TR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
T-24	NVLacphCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGrBeXdKSzVyPUKuOFgxOzdizszN	MlzXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
GOTO	M3vPR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MknzTWM2OD1{LkWzNFE{KM7:TR?=	NGfwNHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
MV-4-11	M3rrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYjJR\|UxRTJwNUmxOlkh\|ryP	M{LDc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
DMS-114	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX7JR\|UxRTJwNk[zOFUh\|ryP	Mo\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
MHH-NB-11	MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NI\3cFNKSzVyPUKuO\|AzQTlizszN	NWLmc4ZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
CHP-212	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWnJR\|UxRTJwOEKwPVEh\|ryP	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
DMS-273	MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mmn5TWM2OD1{LkmwNlA4KM7:TR?=	NU\teYVyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
SF295	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NX;iWJhZUUN3ME2zMlAzPTl5IN88US=>	M4GwdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
NCI-H1563	MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGrFXY5KSzVyPUOuNVUxODVizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NCI-H446	NFrBXI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYTFOlA4UUN3ME2zMlIzQDB3IN88US=>	NWewc5VQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
HCC1806	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUfJR\|UxRTNwMke2OVch\|ryP	M3XNWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
SF126	Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFjudZhKSzVyPUOuN\|AxOTdizszN	NGDFbGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
SW982	NEDUeZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4rTSGlEPTB;Mz6zN\|g4PSEQvF2=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
ES8	M4LJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYnJXIFmUUN3ME2zMlM1QTl7IN88US=>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
SCC-4	MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2nEdGlEPTB;Mz61NFM6PiEQvF2=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
RPMI-8226	NVXUPItvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVfkTnZoUUN3ME2zMlYzPjF4IN88US=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
EW-11	NVThWndHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4X1WmlEPTB;Mz62N\|AzOiEQvF2=	Mkj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
COR-L105	MmGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHnwVXdKSzVyPUOuOlM{OzRizszN	NU\ZTJY5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
ES1	M3LKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3f1XmlEPTB;Mz64N\|A6PCEQvF2=	MnHnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
KMOE-2	NFPLXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFnNbYxKSzVyPUOuPVE5ODhizszN	NWHhNnNLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
ABC-1	NIHDTndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Moe2TWM2OD1\|LkmzPVEyKM7:TR?=	NHmyTYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
NCI-H526	M4LoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX3QPIRkUUN3ME2zMlk6OTJ4IN88US=>	NGHtOI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
HCC1395	M2m2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH;lSJhKSzVyPUOuPVk1QDRizszN	NW\OTVRmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
DU-145	M{XrUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmfPTWM2OD12LkGyPFI2KM7:TR?=	MnPQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
JEG-3	M4DORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXGwOWs2UUN3ME20MlE2QTF4IN88US=>	NEfwXno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
HCC1187	NUTDXoJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWDJR\|UxRTRwMkG1PVch\|ryP	NIm2OGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
LC-2-ad	M4HlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXTJR\|UxRTRwMkKxO\|ch\|ryP	M1W2Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
ONS-76	NHnrTZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4fmVWlEPTB;ND6yOFE6OiEQvF2=	NV3xbJlqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
CAL-27	NWXOZmJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWTJR\|UxRTRwMkSzOFQh\|ryP	NWjMO5UyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
8-MG-BA	M4G1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHToOZhKSzVyPUSuNlY3PThizszN	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
HGC-27	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFTtXoFKSzVyPUSuNlk3PiEQvF2=	NHH0ZZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
Hs-578-T	M2TlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVfaR2xkUUN3ME20MlMyPDZ6IN88US=>	M{DxPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
EW-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NX75d5EyUUN3ME20MlU{ODF2IN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
SW1573	NXvaV4hZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUfJR\|UxRTRwNUWxOlMh\|ryP	M2fwUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
SNU-423	NYry[oNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmK2TWM2OD12Lk[wO\|kh\|ryP	MkLaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
HOS	NIP1N41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWDRR\|I5UUN3ME20MlY6PzdizszN	Ml\PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
LB1047-RCC	MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M33lbWlEPTB;ND64NVQyQCEQvF2=	NV64bXNURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
ChaGo-K-1	NXT5WVNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml3OTWM2OD12Lki5NFQ5KM7:TR?=	NVrMZm9iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
A3-KAW	M3KxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVPJNlhTUUN3ME20Mlk4OzV{IN88US=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
CAS-1	M{jHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXzJR\|UxRTRwOUm5NFgh\|ryP	M1e3T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
NBsusSR	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUHJR\|UxRTVwMEO1NVQh\|ryP	Mo\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
KM12	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mln6TWM2OD13LkK5PFI4KM7:TR?=	NIHmOJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
NCI-H1155	NIfxZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH\WToZKSzVyPUWuN\|gyQDVizszN	M{HHeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
EFM-19	NEC3bplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4TTV2lEPTB;NT60NVc{PyEQvF2=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
D-392MG	NIjiRmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MomzTWM2OD13LkW3PFQ6KM7:TR?=	NU\RTIdKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
JVM-3	M4fIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3LXSWlEPTB;NT63NlMzPSEQvF2=	Mk\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
EW-16	NUjRNppHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWLDepNsUUN3ME21Mlc2PTh\|IN88US=>	NXfLeGg3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
KARPAS-45	NYT6cWNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWXCVIhKUUN3ME21Mlg1OzJ3IN88US=>	NVnZXohtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NCI-H28	M1\wUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlrrTWM2OD13Lki3PVE5KM7:TR?=	NYPZR4pGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
COLO-829	MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYjJR\|UxRTVwOUG1NFQh\|ryP	MmHkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
KM-H2	MoTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkLvTWM2OD13LkmyN\|k2KM7:TR?=	NXjUendRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NCI-H82	NGHQS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHjxe2NKSzVyPUWuPVI4PzFizszN	M3vMT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
OAW-42	NGP3WoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnTnTWM2OD13Lkm4PFIyKM7:TR?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
A704	Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX3IT\|ljUUN3ME22MlExPTd2IN88US=>	NV[3OJdHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NCI-H1048	MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHPuPHVKSzVyPU[uNVA2QTlizszN	M{j2bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
LOXIMVI	M2LHSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnfyTWM2OD14LkGxNlQ5KM7:TR?=	NWfIOFhCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
MKN45	NEXYZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFyyZpZKSzVyPU[uNlYxOTZizszN	MmPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
D-502MG	NVixXpBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXLu[2JpUUN3ME22MlI5QDV5IN88US=>	NH\iS3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
HUTU-80	NIf4NlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVHJR\|UxRTZwNEG2PFgh\|ryP	M3WxVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
S-117	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnjTTWM2OD14LkWwNlY4KM7:TR?=	Ml3MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
HCC1569	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVzCWnNVUUN3ME22MlU{PzN5IN88US=>	NYPBdpZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
J-RT3-T3-5	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{P4O2lEPTB;Nj61OFU4OiEQvF2=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
OC-314	NULkVXF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MorQTWM2OD14LkmxNVU6KM7:TR?=	NUD1Nm1iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
SNU-449	Moi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWnJR\|UxRTdwMEGwO\|Ih\|ryP	NXHZUFZ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NCI-H720	NUHsd2Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYHFcpFZUUN3ME23MlE6OzR3IN88US=>	Mk\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
KP-N-YS	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{n5UmlEPTB;Nz6yNFczKM7:TR?=	NEfBWoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
IGROV-1	NVW1V4RVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFnrR2lKSzVyPUeuN\|I{QDZizszN	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
SK-PN-DW	MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFLzbGpKSzVyPUeuOFgyPSEQvF2=	MnG0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
HCC1419	NH7LWmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX3RVJNIUUN3ME23MlU{KM7:TR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
HAL-01	NUWzNJltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIf0OZVKSzVyPUeuOlA3PDRizszN	M1vscFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
HCC2998	NUXtfZIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkjtTWM2OD15Lk[wO\|Q{KM7:TR?=	NHfZS\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
SK-N-FI	M1HD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHrpTYVKSzVyPUeuOlMxOzNizszN	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
GI-ME-N	NXPqeZJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NG\3fnBKSzVyPUeuOlQ6OzRizszN	NVy0fmJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
SW1088	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2DSVWlEPTB;Nz62OVgzPiEQvF2=	MoT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
IA-LM	NVPZclRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYTJR\|UxRTdwNki2NVMh\|ryP	M{fVVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
SK-NEP-1	NIXsPHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmfZTWM2OD15Lk[5OlEh\|ryP	M2[1OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
MDA-MB-415	NGLsNnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXT5cJNsUUN3ME23Mlg6OTh4IN88US=>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
COLO-800	MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXvLU3FwUUN3ME23Mlk1PDl{IN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NCI-H2228	M4jxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXXaUJU3UUN3ME24MlE2Pzh\|IN88US=>	NFLsOFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
D-423MG	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NU\ITHRDUUN3ME24MlIyPzJizszN	NGr1VWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
TE-1	NIDXdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmjYTWM2OD16LkS0N\|E3KM7:TR?=	M3LUUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
NOS-1	NYDsPY5iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml\yTWM2OD16LkWxOVM1KM7:TR?=	M1uxcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
8505C	Mlv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGXVSWlKSzVyPUiuOlQ5OjRizszN	NI\PVlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
HEC-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFfRV5ZKSzVyPUiuO\|g1OzlizszN	M4DabFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
TE-11	MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWDzbVlxUUN3ME24Mlk6PTVzIN88US=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
CTB-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHnTfYJKSzVyPUmuNFE1OzNizszN	M{XGS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
TGBC11TKB	NWLCfolzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYLubGNvUUN3ME25MlAzOjRzIN88US=>	Mn7wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
NB17	M1vCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYDzUGlJUUN3ME25MlE5QDdizszN	Ml:wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
Becker	NHHLWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn3uTWM2OD17LkSxPVQ1KM7:TR?=	M3L6TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
SN12C	NVjpXllwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUPMVnhOUUN3ME25MlQ2OjN2IN88US=>	NEXZ[Yw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
COLO-320-HSR	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NX25NmdiUUN3ME25MlYxOjN5IN88US=>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
D-283MED	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEfHWG9KSzVyPUmuOlMxPzJizszN	M{P1SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
D-263MG	NGPhTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmfETWM2OD17LkizN\|g1KM7:TR?=	MmHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
MEL-JUSO	NXLOTI82T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWPJR\|UxRTlwOUCxNlch\|ryP	MlTsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
T98G	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2H3Z2lEPTB;OT65NFIxOyEQvF2=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
HLE	M37BO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVjkWG9RUUN3ME25MlkxQTB7IN88US=>	NX7kdHRPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
Ca9-22	NWHWUJRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFexNo1KSzVyPUGwMlA3PjVizszN	NIDjcWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
OS-RC-2	NGfHfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXnJR\|UxRTFyLkGwOFUh\|ryP	MlrEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
T47D	MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1;pOmlEPTB;MUCuNVU2KM7:TR?=	M3u1S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
GI-1	M4LRdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUDJR\|UxRTFyLkO1N\|Mh\|ryP	NFfvNIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
NUGC-3	MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIrkUHRKSzVyPUGwMlQ1ODJizszN	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
MDA-MB-361	NY[0VXVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4nmXmlEPTB;MUCuOFQ{OiEQvF2=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
SCC-15	M37Ocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIrLeoFKSzVyPUGwMlQ4OThizszN	NGXYO3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
KS-1	NWLqTGxsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVrJR\|UxRTFyLk[zNFEh\|ryP	M3;sS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
CAL-12T	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1e2XmlEPTB;MUCuOlM3OSEQvF2=	NHrR[489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
OVCAR-4	NIrhdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3uwVWlEPTB;MUCuO\|A3QCEQvF2=	M3foVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
HuP-T4	M33U[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWTCOZZXUUN3ME2xNU4xOzJ6IN88US=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NCI-H358	M2O1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3nSTmlEPTB;MUGuNlY2PyEQvF2=	NUXM[pVbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
HO-1-N-1	M1rCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4DYS2lEPTB;MUGuN\|M6QCEQvF2=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NH-12	NIm0fVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV\JR\|UxRTFzLkWzO\|gh\|ryP	MmjXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
MOLT-4	NIi3Zo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVLrXm9pUUN3ME2xNU42QTh3IN88US=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
K-562	NWT3R3pbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NI\rUHhKSzVyPUGxMlczPDhizszN	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
ES6	NUHMepQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4HGU2lEPTB;MUGuPFU5OSEQvF2=	NWLQbmxyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
RO82-W-1	NXzMNWU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mke1TWM2OD1zMT65NFY1KM7:TR?=	NEfhUm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
Ramos-2G6-4C10	M1fnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUXZcZZ7UUN3ME2xNU46OzJizszN	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
23132-87	NIjIeppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnH6TWM2OD1zMj6wPFIyKM7:TR?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
A549	NIrqWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVvJR\|UxRTF{LkOyPFUh\|ryP	MlfSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
NCI-H23	NGi3[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV3JR\|UxRTF{LkWwNlYh\|ryP	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
H9	Mlr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEj4UppKSzVyPUGyMlU2PzdizszN	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
LB771-HNC	M3HHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHizPIJKSzVyPUGyMlc3PSEQvF2=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
QIMR-WIL	NF7TdIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF:weZZKSzVyPUGyMlgzPThizszN	MmnRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
HSC-3	NFPEeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1LOXWlEPTB;MUKuPVI4PiEQvF2=	MmqzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
PFSK-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnPvTWM2OD1zMj65OVA4KM7:TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
ETK-1	NXL6ZWZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M131dGlEPTB;MUOuNFc4QSEQvF2=	NXPTcXlQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
SW1710	NWjFU5VIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1;OUGlEPTB;MUOuN\|Y1OSEQvF2=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
COLO-684	MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV7JR\|UxRTF\|LkS1OFEh\|ryP	M3K0N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
RPMI-7951	NYDw[oVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MULJR\|UxRTF\|LkWxN\|Yh\|ryP	M4TtUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
A101D	MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXLJR\|UxRTF\|LkWzOFkh\|ryP	NYjGb4hYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
KE-37	NIHIV5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{Hse2lEPTB;MUOuOVg5PyEQvF2=	NVPwfWszRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
SiHa	NUHTZYhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYiyTmV3UUN3ME2xN{45OzR4IN88US=>	NF;MeFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
NCI-H226	NULi[YVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGj4[plKSzVyPUGzMlg5ODhizszN	NIi5Vo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
DB	MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2XpN2lEPTB;MUOuPVkzQCEQvF2=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
HT-1197	Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFPKVWVKSzVyPUG0MlA5ODlizszN	NFrmPVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
SBC-5	NELsbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmHSTWM2OD1zND6xN\|YzKM7:TR?=	NYnqdHdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
VMRC-RCZ	NFnyZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoPwTWM2OD1zND61O\|c1KM7:TR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
697	MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoLZTWM2OD1zND62Nlch\|ryP	NXPMOYRSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
OMC-1	NWDmSFN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnvITWM2OD1zND63PFg5KM7:TR?=	NVTKeoJ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
SKG-IIIa	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEj6SoVKSzVyPUG0MlgxODFizszN	M1jQ[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
DOK	NEfLU\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFLaUpZKSzVyPUG0Mlk6OzNizszN	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NCI-H2029	NHXYb4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV\Ye\|B3UUN3ME2xOU4{PjB{IN88US=>	NF;KTVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
NCI-H2009	NF3nO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUC3c45GUUN3ME2xOU42ODl3IN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
LK-2	NYPjPZZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlPBTWM2OD1zNT62OFQ6KM7:TR?=	NYXoSZRQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NCI-H661	M2rMdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{DTNWlEPTB;MUWuPVA4PSEQvF2=	Mo\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
GT3TKB	MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn\rTWM2OD1zNj6wOlc3KM7:TR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
GP5d	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NETEVWpKSzVyPUG2MlM1OiEQvF2=	NYD0[JJ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
SK-MEL-2	M3;hO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUfsZVZXUUN3ME2xOk41PDh3IN88US=>	NWn2bpZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
SK-UT-1	M{PlWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{\HRWlEPTB;MU[uOVY2KM7:TR?=	NXrGSI5PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NB7	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUfBPXhOUUN3ME2xOk43QTdzIN88US=>	NVfhemUyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NCI-H460	M{K5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVXNSVRyUUN3ME2xOk44OzJ4IN88US=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
8305C	NHHyXY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NY\XOZVtUUN3ME2xOk44QDd5IN88US=>	M2Pp[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
CaR-1	NGq4d3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVe0dlI5UUN3ME2xOk45OTFzIN88US=>	Ml\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
D-247MG	NYLFOWZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFH1c\|VKSzVyPUG2Mlg3OjVizszN	MlT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
LoVo	M4\KTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXLJR\|UxRTF4Lkm0PFgh\|ryP	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NCI-H2405	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{LZdGlEPTB;MUeuNVkxQCEQvF2=	NVTjVYxzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
AU565	NXnmc4pnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVLJR\|UxRTF5LkKyOUDPxE1?	NYPmVoRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
OCI-AML2	MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXvETJlUUUN3ME2xO{42OzF5IN88US=>	NHfzdmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
22RV1	NUfqd\|FrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUPxNFhQUUN3ME2xO{42QDh2IN88US=>	NV7xdXFMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
HT-144	M{j2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mm\UTWM2OD1zNz62OVk5KM7:TR?=	M1rpTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
HuO9	M3;PcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX\JR\|UxRTF5LkewN\|Eh\|ryP	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
Daoy	M1r2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYH4N495UUN3ME2xO{44OTh2IN88US=>	M{\JVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
SJRH30	NH;ISFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoTsTWM2OD1zNz64OFg6KM7:TR?=	M1PIV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
CHL-1	MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHW0W5dKSzVyPUG3MlkzPDlizszN	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
J82	M1PBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEj5d5lKSzVyPUG3Mlk3OzVizszN	MnjKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
COR-L23	NF\wWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV;JR\|UxRTF6LkCwNVEh\|ryP	Mn;HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
SNU-C2B	NIDYeWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MY\JR\|UxRTF6LkKyO\|Yh\|ryP	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NCI-H1770	NXnCNoRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{jROWlEPTB;MUiuOFYyPSEQvF2=	NGi0O489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
MHH-PREB-1	NGfrNIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYfTenVXUUN3ME2xPE42Pjl5IN88US=>	M3ziV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
ES3	M4fpc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIfLTllKSzVyPUG4MlU5QDNizszN	NHPQdnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
MDA-MB-231	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH3Od3RKSzVyPUG4MlY2ODJizszN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
MN-60	NYfQNYhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mlm2TWM2OD1zOT6wOVkzKM7:TR?=	NGDaO2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
EPLC-272H	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUPZR3h1UUN3ME2xPU4{PzB6IN88US=>	MlXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
SW948	NV\4cnR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3zwU2lEPTB;MUmuN\|k{PCEQvF2=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
MOLT-13	NW\jXplbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlPCTWM2OD1zOT60OVQ3KM7:TR?=	MoDJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
HL-60	NEjnfWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXPjV45NUUN3ME2yNE4zOTRzIN88US=>	M{jmO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
CP50-MEL-B	NUj5UmpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFTTPWNKSzVyPUKwMlQ4PDhizszN	M4PY[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
NTERA-S-cl-D1	NVr5TIQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2[3fWlEPTB;MkCuOFk4QCEQvF2=	Ml\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
KINGS-1	Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVfDOHVsUUN3ME2yNE44QTZ5IN88US=>	NH;PZo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
DOHH-2	NVrNNGFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVTJR\|UxRTJyLkmwOkDPxE1?	NY\vfFFrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
BB65-RCC	MkfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWTJR\|UxRTJyLkmyPFUh\|ryP	M1;vWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
NB12	NXHQdJk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXvJR\|UxRTJzLkCzPVQh\|ryP	M3LnbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
KY821	MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M33MNWlEPTB;MkGuOVgzKM7:TR?=	Ml;NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
PSN1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVXSXmFIUUN3ME2yNU43PDV\|IN88US=>	M1XNbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
EGI-1	NHrFUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4\ZRWlEPTB;MkGuO\|Q2PCEQvF2=	NWrRXWRoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
CTV-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4H1d2lEPTB;MkKuN\|A{OSEQvF2=	NIfJSG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
TI-73	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVm0SY1tUUN3ME2yNk4{PDl6IN88US=>	NI\ofXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
LCLC-103H	NEPZeoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYnDWlJDUUN3ME2yNk41PzV{IN88US=>	NF;UV4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
D-542MG	NX;UeWpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYPNOnRGUUN3ME2yNk42PTV6IN88US=>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
ATN-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NX7tXmkxUUN3ME2yNk43PDN7IN88US=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
SK-MEL-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVjJR\|UxRTJ{LkizOlgh\|ryP	NWjDRYdDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
HDLM-2	NYLzNG81T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoXuTWM2OD1{Mz6xOFc5KM7:TR?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
UM-UC-3	Ml7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFnSZ3VKSzVyPUKzMlE6PDRizszN	MkDxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
NCI-H1573	NVnmZWE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MU\JR\|UxRTJ\|LkS2PFEh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NCI-H520	MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{LlXmlEPTB;MkOuOFk1QCEQvF2=	MlzJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
ESS-1	NVPW[FBKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmTVTWM2OD1{Mz64NFU6KM7:TR?=	M3qwXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
COR-L88	NGrLSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mm\zTWM2OD1{Mz65OFc2KM7:TR?=	NFjveVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
TGBC24TKB	Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHfIOIpKSzVyPUK0MlA{OTJizszN	M3fv[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
HCC1937	NV;XepRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlO0TWM2OD1{ND6xJO69VQ>?	NFzTUJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
RS4-11	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnvUTWM2OD1{ND6xOFIh\|ryP	NVPzOGVFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
HCC38	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnvCTWM2OD1{ND6yN\|k1KM7:TR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
RPMI-2650	M3vUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{\yemlEPTB;MkSuOlE3OiEQvF2=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
P12-ICHIKAWA	NVHQfG45T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFyycFFKSzVyPUK0MlYzPThizszN	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
YAPC	NHzwNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NI\KR4dKSzVyPUK0MlgzOTRizszN	M1TldFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
NB13	NHzrfJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV7JR\|UxRTJ3LkK2NVEh\|ryP	M3LET\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
SK-N-AS	NULz[I5YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHjGR\|VKSzVyPUK1Mlg2QDRizszN	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
SK-N-DZ	NEnpNFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NY\KOFluUUN3ME2yOk4xPDlizszN	NWfZOoRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
LS-411N	NHLXbXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2jkVGlEPTB;Mk[uNlA{QCEQvF2=	NW\FW2FyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NCI-H810	NF\LUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX3JR\|UxRTJ4LkOxNVIh\|ryP	MnLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
NCI-SNU-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmnvTWM2OD1{Nj61OFU1KM7:TR?=	NEe1PXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
HH	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3rR[mlEPTB;Mk[uOVUzQSEQvF2=	MoLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
U-2-OS	NEHn[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYLl[4JlUUN3ME2yOk44Ozh{IN88US=>	M3fJ[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
SF539	M13wPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MluyTWM2OD1{Nj64NFE5KM7:TR?=	NYi5VpVQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NCI-H2052	MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlnCTWM2OD1{Nz6wPFYh\|ryP	NVrnNIl7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
A673	MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYPieGVzUUN3ME2yO{4zOTB{IN88US=>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
WM-115	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX7JR\|UxRTJ5Lke3Olch\|ryP	NGLSTHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
SW48	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4fESGlEPTB;MkeuPFAxPSEQvF2=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NOMO-1	MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIPDepVKSzVyPUK3Mlg2OzJizszN	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
PC-3	M3zDeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX3JR\|UxRTJ5Lki5OFEh\|ryP	NHnoenM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
UMC-11	M4nUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkPwTWM2OD1{Nz65N\|Q{KM7:TR?=	M2rEd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
U-118-MG	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUXJR\|UxRTJ6LkCxNlMh\|ryP	M1Ll[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
NCI-H2452	M4L5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH;hTY1KSzVyPUK4MlA5OjJizszN	NFzkXoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
CAMA-1	MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnjzTWM2OD1{OD64OVY1KM7:TR?=	MoWwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
MC-IXC	NXXjbY5DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmDnTWM2OD1{OT6yN\|Y3KM7:TR?=	M17uOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
ES4	M3HaZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYDJR\|UxRTJ7LkOxO\|Ih\|ryP	M4DzWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
BHT-101	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWnJR\|UxRTJ7LkOyNUDPxE1?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
KP-4	NIrOcJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXu0blk5UUN3ME2yPU42OTZizszN	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
CAL-54	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXnJR\|UxRTJ7LkW0OFUh\|ryP	NFTKOHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
5637	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4XHR2lEPTB;MkmuOlQzOSEQvF2=	NYfOSlR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
MOLT-16	MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGfDb2pKSzVyPUK5MlczPjlizszN	Ml\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
Ca-Ski	NETX[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEe4co9KSzVyPUK5Mlk1PiEQvF2=	MnPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
AsPC-1	M1:3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGrDV\|BKSzVyPUOwMlAzOTJizszN	NWe1cYNwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
MSTO-211H	Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MljVTWM2OD1\|MD6xOUDPxE1?	Mm\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
L-428	NYnkb3FZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEfacVBKSzVyPUOwMlQxPSEQvF2=	NGP4bpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
SW1463	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MY\JR\|UxRTNyLkWzPFMh\|ryP	NYq0c2VxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NCI-H1648	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1Ts[2lEPTB;M{CuOVU4PCEQvF2=	NFrlV4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
CAKI-1	NELWb3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXfJR\|UxRTNyLke3NFIh\|ryP	NXnTOWhURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
YKG-1	Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NELqfXJKSzVyPUOxMlAzPjNizszN	NFX2bVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
A2058	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYPJR\|UxRTNzLkGxOlQh\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
A375	M{LyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{X1NGlEPTB;M{GuNVY6PiEQvF2=	M2rhXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
SNB75	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV3JR\|UxRTNzLkK0N\|Uh\|ryP	MnnMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
SK-HEP-1	M{DUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4niemlEPTB;M{GuOFI4OSEQvF2=	Mn7tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
ME-180	MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MonFTWM2OD1\|MT62OVQzKM7:TR?=	MkCxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
NCI-H209	M{fwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH\5NWNKSzVyPUOxMlgzPDdizszN	M3W5NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
HC-1	MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX\HOGJvUUN3ME2zNk4yPDR4IN88US=>	NVjPV2JORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
LB373-MEL-D	NUTFRVMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mne5TWM2OD1\|Mj6xPVcyKM7:TR?=	NEe0d\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
SNU-387	NEeyUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVLJR\|UxRTN{LkOxPVEh\|ryP	NG[yb2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
C32	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWHrOpJqUUN3ME2zNk4{OzV\|IN88US=>	M3rIelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
EW-13	MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2H6[mlEPTB;M{KuPVQxQCEQvF2=	NH;nUIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
BFTC-905	M4XYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVXJR\|UxRTN\|LkWxN\|Yh\|ryP	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NCI-H1299	M4n3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Ml:wTWM2OD1\|Mz61OlIyKM7:TR?=	MlK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
LU-135	NYDiZ2RVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWWyVHVTUUN3ME2zN{45ODFizszN	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NCI-H2122	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGfFV\|dKSzVyPUOzMlk6PjZizszN	NVzhdGp1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
SK-LMS-1	NV7yfGNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MorWTWM2OD1\|ND60NVA4KM7:TR?=	MkKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
LNCaP-Clone-FGC	NEf5SmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXrJR\|UxRTN2Lki1NVUh\|ryP	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NCI-H1092	MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGnCS4xKSzVyPUO1MlI4PDdizszN	M2GzXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
MS-1	NImzTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX\lPFk{UUN3ME2zOU4{ODN6IN88US=>	M{Xt[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
KYSE-510	MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEnNWZpKSzVyPUO1MlUxPDJizszN	MmnoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
NCI-H1793	M{\jWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkiwTWM2OD1\|NT62OVQ2KM7:TR?=	Mk\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
MIA-PaCa-2	NXvYVJlGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGq3VWFKSzVyPUO2MlA1QTZizszN	NEnxT2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
EW-22	NYn2VmpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFvYUGdKSzVyPUO2MlQxPzJizszN	M3\r[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
IGR-1	MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NILZUZlKSzVyPUO2MlgyQDRizszN	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
HT-1080	M1vIO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1\1WWlEPTB;M{euNVI2KM7:TR?=	MorrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
M14	M2PPdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4PXO2lEPTB;M{euNVY1OiEQvF2=	NYXEVW1nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
786-0	MlLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX74PXdpUUN3ME2zO{4zPzl2IN88US=>	M2rGOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
MZ2-MEL	NIfT[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlHxTWM2OD1\|Nz60OVAyKM7:TR?=	NUWxcpJvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NCI-H510A	MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYXPeXo4UUN3ME2zO{46PDF{IN88US=>	NX;BcJR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
LAN-6	M3zWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVzGR5pIUUN3ME2zO{46PTh{IN88US=>	M1;4TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
SW620	NYKwZWE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUjmSlVOUUN3ME2zPE41QTd2IN88US=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
LB2241-RCC	NVrqUZg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmPJTWM2OD1\|OT64NlA2KM7:TR?=	NUPVd\|B[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
Detroit562	NHm2U3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4PtXmlEPTB;NECuNVI3QCEQvF2=	NVv6XlFCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
HN	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVrJR\|UxRTRyLkG3PFIh\|ryP	M2nBWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
HCT-15	NXe2WWlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWnJR\|UxRTRyLkW5NFch\|ryP	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
C2BBe1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXj6Vm12UUN3ME20NE46OTV5IN88US=>	M{LJSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
A498	M3PNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXv4b\|loUUN3ME20NU4{ODF3IN88US=>	MmfiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
SK-MEL-24	NUnGVJRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4C1SmlEPTB;NEGuOFczPSEQvF2=	NUTVTIR4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
OVCAR-5	M4XGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4jlOmlEPTB;NEGuO\|c3PyEQvF2=	NFnjR4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
NCI-H1792	MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnrETWM2OD12MT65PFIyKM7:TR?=	NUfObYxjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
KOSC-2	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1\SOWlEPTB;NEKuNlY6QSEQvF2=	NV;OOWxGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
Mo-T	Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3rOfWlEPTB;NEKuPFk2QCEQvF2=	Mlz5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
CFPAC-1	M4LuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Ml7xTWM2OD12Mz60PVQ1KM7:TR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
CAL-51	MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NY\YTI1DUUN3ME20N{42PjB3IN88US=>	MnXoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
RH-18	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWfFPJpNUUN3ME20N{45ODVizszN	M4fJSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
EC-GI-10	NVqyRpllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXnSeJh2UUN3ME20N{45OzR5IN88US=>	Mo[1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
HSC-2	NInr[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NILYR4xKSzVyPUS0MlAxQSEQvF2=	M4fPflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
ML-2	MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVfYNFZRUUN3ME20OU4zPjJzIN88US=>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
KNS-81-FD	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH35NGxKSzVyPUS1Mlc{PjVizszN	NYPlXJhzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NB6	NV6wTXBNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NG\vZ\|NKSzVyPUS2MlEyOSEQvF2=	NWfxSWxNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
MCF7	NFu2NoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIHPdZlKSzVyPUS2MlU2OzNizszN	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
P30-OHK	NVr5[4F{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmTOTWM2OD12Nj64NVE4KM7:TR?=	NFLpbWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
BPH-1	NGPtfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFLHUJRKSzVyPUS2Mlk5ODVizszN	M2j6VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
U251	MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFrzNVNKSzVyPUS2Mlk6PCEQvF2=	MmXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
MKN1	M{nSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NY\LV3pYUUN3ME20O{42OTN5IN88US=>	NFHqRWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
A431	M1jEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUjJR\|UxRTR5LkizN\|gh\|ryP	MmraQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
C8166	NHLiN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX;JR\|UxRTR7LkKwN\|kh\|ryP	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
HEL	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NG\kOVJKSzVyPUS5MlQxPjRizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
RMG-I	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkPPTWM2OD12OT60OFQ1KM7:TR?=	NXzvSoNTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
CAL-72	M2DIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mli1TWM2OD12OT62NFc2KM7:TR?=	NHvpT5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
SW962	NX3NclE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{DYT2lEPTB;NEmuPVM{OiEQvF2=	NITNNoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
MCF7	M1LGTWFvfGmycn;sbYZmemG2aY\lJIF{e2G7	M3\iOlUh\GG7cx?=	NHHJPVFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgOUBl[Xm\|IHL5JHNTSiCjc4PhfUwhT0l3MDC9JFAvQTdizszNMi=>	MoTXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6Mkm1OFkoRjJ\|OEK5OVQ6RC:jPh?=
MDA-MB-468	NFj6c\|JCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=	MkDDOUBl[Xm\|	MkL0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuPDZ6IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDViZHH5d{BjgSCVUlKgZZN{[XluIFfJOVAhRSBzLkOg{txONg>?	M1nFclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEK5OVQ6Lz5{M{iyPVU1QTxxYU6=
HCC1954	Mm\QRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	NH;IS4Y2KGSjeYO=	MnrqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ1OxPVU1KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFUh\GG7czDifUBUWkJiYYPzZZktKEeLNUCgQUAzNjdizszNMi=>	NGThOGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iyPVU1QSd-MkO4Nlk2PDl:L3G+
SKBR3	MnHCRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	MnTJOUBl[Xm\|	NHzrTm1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLRnI{KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFUh\GG7czDifUBUWkJiYYPzZZktKEeLNUCgQUA{NjhizszNMi=>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh{OUW0PUc,OjN6Mkm1OFk9N2F-
MDA-MB-231	MUHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	NVfHcpZHPSCmYYnz	Ml\NRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDViZHH5d{BjgSCVUlKgZZN{[XluIFfJOVAhRSB5LkOg{txONg>?	NETldoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iyPVU1QSd-MkO4Nlk2PDl:L3G+
MCF7	NWi3R3FJS3m2b4TvfIlkcXS7IHHzd4F6	Mo[5OUBl[Xm\|	M{C0VWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOUBl[Xm\|IHL5JHNTSiCjc4PhfUwhT0l3MDC9JFIvOyEQvF2u	M2PxVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OE[3OFA{Lz5{NEi2O\|QxOzxxYU6=
MDA-MB-468	NG[xU4JEgXSxdH;4bYNqfHliYYPzZZk>	M1rFdlUh\GG7cx?=	NVTrNWJFS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{Bi\nSncjC1JIRigXNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNk45KM7:TT6=	NVPCco54RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4Olc1ODNpPkK0PFY4PDB\|PD;hQi=>
SKBR3	NWPC[nFZS3m2b4TvfIlkcXS7IHHzd4F6	M1T0U\|Uh\GG7cx?=	MWHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT2JTOyClZXzsd{Bi\nSncjC1JIRigXNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gOE43KM7:TT6=	NH:3[mE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi2O\|QxOyd-MkS4Olc1ODN:L3G+
MDA-MB-231	MmHGR5l1d3SxeHnjbZR6KGG\|c3H5	MVi1JIRigXN?	MlXzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB3IHThfZMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMUGg{txONg>?	NHXwOGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi2O\|QxOyd-MkS4Olc1ODN:L3G+
Saos-2	M4DleJFJXFNiYYPzZZk>		M4q0eZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-12	M2rQfZFJXFNiYYPzZZk>		MmTEdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy\|	NYi0RnFYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	NHnYR\|ByUFSVIHHzd4F6		M{XG[pFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	NWDH[pkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2	NEmwV5FyUFSVIHHzd4F6		MX\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	M4nkeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	M4q1VJFJXFNiYYPzZZk>		Ml;MdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	NYrYTotRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	MlTydWhVWyCjc4PhfS=>		NULISZlGeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM>	MlzVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh18	Ml20dWhVWyCjc4PhfS=>		MoT1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN?	NYKwcXFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
HUVEC	MXPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	NHjXPJoyKGi{	MofoRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDWSWdHNXO2aX31cIF1\WRiSGXWSWMh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KHC{ZXnuZ5Vj[XSnZDDmc5IhOSCqcjDmc4xtd3enZDDifUBi\GSrdHnvckBw\iCYRVfGJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAxODVizszNMi=>	NVz4[IxrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRkOqRV3CUFww[T5?
HUVEC	M{TzRmFvfGmycn;sbYZmemG2aY\lJIF{e2G7	NH3aXIoyKGi{	NYixO5psSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBXTUeILYP0bY12dGG2ZXSgTHVXTUNiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IIDy[Ylv[3WkYYTl[EBnd3JiMTDodkBnd2yub4fl[EBjgSCjZHTpeIlwdiCxZjDWSWdHKG2nYYP1doVlKGGodHXyJFczKGi{czDpckBxemW\|ZX7j[UBw\iCjbHL1cYlvKGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFAzPyEQvF2u	NF72eXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,S2iHTVLMQE9iRg>?
A549	NX[4UmxtSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=	NGjoPJg1QCCqcoO=	MmnvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDWSWdHNXO2aX31cIF1\WRiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA1QCCqcoOgZpkhS0ONODDhd5NigSxiSVO1NEA:KDJ{LkSg{txONg>?	NInab4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,S2iHTVLMQE9iRg>?
HepG2	MVPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	NXPsZWxHPDhiaILz	MkfIRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDWSWdHNXO2aX31cIF1\WRiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KEOFS{igZZN{[XluIFnDOVAhRSB\|OD63JO69VS5?	Mn3KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQmNpTU2ETEyvZV4>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-c-kit / c-kit / p-AKT / AKT / p-ERK / ERK / p-STAT3 / STAT3 / p-STAT5 / STAT5 / p-S6K / S6K / p-S6 / S6; PubMed: 31205508 Ther Adv Med Oncol Immunoblotting analysis of indicated proteins in c-KIT mediated signaling pathways of GIST-T1, GIST-882, GIST-48B, and GIST-5R cell lines. PARP / cleaved PARP / caspase-3 / cleaved caspase-3; PubMed: 31205508 Ther Adv Med Oncol Immunoblotting analysis of apoptosis-related proteins after axitinib treatment in human GIST cell lines. Imatinib and sunitinib were used as positive controls.	31205508
Immunofluorescence	alpha-tubulin; PubMed: 26474283 Oncotarget Representative images of RCC cells treated as above described, and then immunostained with anti-α-tubulin antibody. Bar: 50 μM	26474283
Growth inhibition assay	Cell viability ; PubMed: 26474283 Oncotarget A. A-498 and Caki-2 RCC cell lines were cultured up to 96 h with different doses of axitinib. Cell viability was determined by MTT assay. Data shown are expressed as mean ± SD of three separate experiments; *p < 0.01 vs vehicle-treated cells. B. RCC cell 䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕	26474283

In vivo

Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). ^[1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 ﬂank xenografts. ^[2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. ^[3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay: ^[1]	- Collapse Cellular receptor kinase phosphorylation assay: Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research: ^[2]	- Collapse Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells Concentrations: 1 nM - 10 μM Incubation Time: 72 hours Method: Cells are seeded in a 96-well plate at a density of 5 × 10⁴ and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks). Dosages: 10, 30 or 100 mg/kg Administration: Oral daily (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	35 mg/mL warmed (90.56 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Axitinib (AG 013736) SDF

Molecular Weight	386.47
Formula	C₂₂H₁₈N₄OS
CAS No.	319460-85-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04941768	Recruiting	--	Carcinoma Renal Cell	Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany\|Merck Serono GmbH an affiliate of Merck KGaA Darmstadt Germany	August 9 2021	--
NCT04682587	Active not recruiting	Drug: Axitinib\|Drug: Avelumab\|Drug: Pembrolizumab	Renal Cell Carcinoma	Pfizer	February 24 2021	--
NCT04669366	Recruiting	Drug: sunitinib\|Drug: axitinib	Kidney Neoplasms	Pfizer	January 20 2021	--
NCT04626128	Recruiting	Drug: CLS-AX\|Drug: Anti-VEGF	Neovascular Age-related Macular Degeneration	Clearside Biomedical Inc.	December 15 2020	Phase 1\|Phase 2
NCT04637204	Completed	Drug: Cabozantinib\|Drug: Axitinib	Renal Cell Carcinoma	Ipsen	November 24 2020	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
We would like to store at -80℃ after it dissolved in CMC. Do you have any infomation about the suggested concentration in CMC?
Answer:
Axitinib in 0.5% CMC at up to 30mg/ml is a suspension for oral gavage administration only. We don't suggest customer to freeze down the solution but to make fresh if possible. Customer can store it for 1-2 weeks at 4 degree for continuous use.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Selective VEGFR Inhibitors

Vandetanib (ZD6474) : VEGFR2-selective, IC50=40 nM.
Most Potent VEGFR Inhibitor

Cabozantinib (XL184, BMS-907351) : VEGFR2, IC50=0.035 nM.
FDA-approved VEGFR Inhibitor

Regorafenib (BAY 73-4506) : Approved by FDA for metastatic colorectal cancer and advanced gastrointestinal stromal tumors.
Classic VEGFR Inhibitor

Nintedanib (BIBF 1120) : Potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM. Phase 3.

Related VEGFR Products

SU5402 ^New

SU5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGF-Rβ, respectively.
Erlotinib (OSI-774) ^New

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Bemcentinib (R428) ^New

Bemcentinib (R428, BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
Regorafenib (BAY 73-4506)

Regorafenib (BAY 73-4506, Fluoro-Sorafenib, Resihance, Stivarga) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit (c-Kit), RET (c-RET) and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively. Regorafenib induces autophagy.
Cabozantinib (BMS-907351)

Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.
Nintedanib (BIBF 1120)

Nintedanib (BIBF 1120, Intedanib, Vargatef, Ofev) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.
Vandetanib (ZD6474)

Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay. It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM. No activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib (ZD6474) increases apoptosis and induces autophagy by increasing the level of reactive oxygen species (ROS).
Lenvatinib (E7080)

Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β in cell-free assays. Lenvatinib (E7080) also inhibits FGFR1-4, PDGFR, Kit (c-Kit), RET (c-RET), and shows potent antitumor activities. Phase 3.
Pazopanib

Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms/CSF1R with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. Pazopanib induces cathepsin B activation and autophagy.
Pazopanib HCl (GW786034 HCl)

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. Pazopanib induces autophagic Type II cell death.

Features:A multi-kinase inhibitor.

Choose Your Country or Region

By Signaling Pathways

By product type

Axitinib (AG 013736)